Homburger advised Idorsia on a placement of 16.4 m shares through an accelerated bookbuilding process, raising gross proceeds of CHF 65.6 m in aggregate, at an offer price of CHF 4.00 per offered share. In connection with the
Tags :Homburger
Homburger advised Straumann Holding on its issuance of CHF 250 m fixed rate senior bonds, carrying a coupon of 0.550%. The bonds are governed by Swiss law, have been admitted to trading and are set for listing
Homburger advised UBS Group on its issuance of AUD 1.25 bn Tier 1 capital notes with an equity conversion feature. The issuance The notes are ‘high-trigger’ regulatory capital instruments that count toward UBS Group’s Swiss going-concern
Homburger advised 21Shares on the listing of three new series of crypto-linked exchange ETPs as well as the cross-listing of three existing series of crypto-linked ETPs – all on the SIX Swiss Exchange. The series Amognst
Homburger advised Luzerner Kantonalbank on the issuance of CHF 200m Tier 2 bonds, carrying a coupon of 1.400%. Luzerner Kantonalbank and UBS served as joint-lead managers on the transaction. The bonds are set to listing on the
Landis+Gyr divested its EMEA business to private equity investor Aurelius, for an enterprise value of USD 215 m. The divestment encompasses five production sites across EMEA and involves a workforce of approximately 2,700 employees. In connection
Homburger advised Santhera in connection with its CHF 20 m royalty monetization and convertible bond financing. The deal encompassed an USD 13 m royalty monetization financing with R-Bridge, an affiliate of Singapore-based healthcare-focused investment firm CBC Group.
Homburger advised UBS Group in connection with the issuance of USD 1.25 bn Fixed Rate/Floating Rate Callable Senior Notes due December 2029, USD 700 m Floating Rate Callable Senior Notes due December 2029, USD 1 bn Fixed Rate/Floating
Homburger advised biopharmaceutical company Madrigal in connection with its new USD 500 m senior secured credit facility from Blue Owl Capital. Madrigal’s Swiss subsidiary, Madrigal Pharmaceuticals GmbH, acceded as guarantor and security provider to the
Homburger advised Givaudan in connection with the issuance of EUR 500 m guaranteed bonds due 2029, yielding 2.875 %. Guaranteed by the company itself, the bonds are governed by English law and listed on Euronext Dublin. The Homburger team
